Sassicaia Capital Advisers’s Viking Therapeutics VKTX Stock Holding History

Sassicaia Capital Advisers’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-17,500	Closed	-$464K	–	60
2025 Q2	$464K	Buy	+17,500	New	+$461K	0.29%	24
2024 Q4	–	Sell	-10,000	Closed	-$633K	–	23
2024 Q3	$633K	Sell	10,000 -9,500	-49%	-$557K	1.84%	9
2024 Q2	$1.03M	Sell	19,500 -20,800	-52%	-$1.36M	4.18%	9
2024 Q1	$3.3M	Sell	40,300 -17,500	-30%	-$779K	14.02%	2
2023 Q4	$1.08M	Buy	+57,800	New	+$756K	9.3%	3
2023 Q2	–	Sell	-10,000	Closed	-$167K	–	56
2023 Q1	$167K	Buy	+10,000	New	+$103K	0.14%	35

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sassicaia Capital Advisers's VKTX Position: Q3 2025 in Review

Sassicaia Capital Advisers sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 17,500 shares — an estimated $464K sold.

Sassicaia Capital Advisers first reported a position in VKTX in Q1 2023 and held it in 6 quarters. The position peaked at $3.3M in Q1 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

Sassicaia Capital Advisers reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
Sassicaia Capital Advisers sold 17,500 Viking Therapeutics shares in Q3 2025, an estimated $464K.
Sassicaia Capital Advisers first reported a position in Viking Therapeutics in Q1 2023 and held it in 6 quarters.
Sassicaia Capital Advisers's Viking Therapeutics position peaked at $3.3M in Q1 2024.
370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Sassicaia Capital Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.